le meta-analisi dei trial randomizzati sullintera classe dei GLP-1 AR non evidenziano un incremento consistente di neuropatia ottica ischemica (Silverii et al., 2025), e gli studi di farmacovigilanza che hanno analizzato i database FAERS e VigiBase non hanno rilevato un segnale a carico di tirzepatide (Lakhani et al., 2025)
Not a bit
Many clients notice a refreshed appearance and improved hydration shortly after treatment
The gene expression data is particularly compelling
BCBS of Michigan, 2024 coverage policy announcement Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older one of 13 states covering GLP-1s for obesity as of January 2026
Clauss, M., Grard, P., Mosca, A